The results showed that insulin-loaded nanoparticles could be stable in gastric juice and effectively released in intestinal fluid when simulated digestion in vitro, as our expectations, and it could alleviate type 2 diabetic mice by reducing fasting blood glucose values. The gene discussed is INS; the disease is type 2 diabetes mellitus.